Literature DB >> 27046369

Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.

Xinyang Hua1, Natalie Carvalho1, Michelle Tew1, Elbert S Huang2, William H Herman3, Philip Clarke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27046369      PMCID： PMC4886177          DOI： 10.1001/jama.2016.0126

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Why is there no generic insulin? Historical origins of a modern problem.

Authors:  Jeremy A Greene; Kevin R Riggs
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

2.  Change in medical spending attributable to diabetes: national data from 1987 to 2011.

Authors:  Xiaohui Zhuo; Ping Zhang; Henry S Kahn; Barbara H Bardenheier; Rui Li; Edward W Gregg
Journal:  Diabetes Care       Date:  2015-01-15       Impact factor: 19.112

3.  Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.

Authors:  Jing Luo; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2015-10       Impact factor: 21.873

4.  Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.

Authors:  Kasia J Lipska; Joseph S Ross; Holly K Van Houten; David Beran; John S Yudkin; Nilay D Shah
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272
  4 in total
  40 in total

Review 1.  Who Will Be Responsible for the Dialysis Bill? A Case Report and Narrative Review of Insulin Affordability 100 Years After the Discovery of Insulin.

Authors:  Alheli Arce Gastelum; Sima Maraqa; Walter Ariel Marquez Lavenant; Ammara Khan; Robert S McMahon; Azka Latif; Theresa A Townley
Journal:  J Gen Intern Med       Date:  2021-06-02       Impact factor: 5.128

2.  Cost-Related Insulin Underuse Among Patients With Diabetes.

Authors:  Darby Herkert; Pavithra Vijayakumar; Jing Luo; Jeremy I Schwartz; Tracy L Rabin; Eunice DeFilippo; Kasia J Lipska
Journal:  JAMA Intern Med       Date:  2019-01-01       Impact factor: 21.873

3.  The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).

Authors:  William H Herman; Barbara H Braffett; Shihchen Kuo; Joyce M Lee; Michael Brandle; Alan M Jacobson; Lisa A Prosser; John M Lachin
Journal:  J Diabetes Complications       Date:  2018-06-12       Impact factor: 2.852

4.  Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries.

Authors:  Bruce E Landon; Alan M Zaslavsky; Jeffrey Souza; John Z Ayanian
Journal:  J Gen Intern Med       Date:  2018-02-09       Impact factor: 5.128

5.  A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.

Authors:  Susan J Guzman
Journal:  Diabetes Spectr       Date:  2020-02

6.  Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.

Authors:  Jing Luo; Nazleen F Khan; Thomas Manetti; Jim Rose; Ani Kaloghlian; Balu Gadhe; Sachin H Jain; Joshua J Gagne; Aaron S Kesselheim
Journal:  JAMA       Date:  2019-01-29       Impact factor: 56.272

Review 7.  Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?

Authors:  Laura N McEwen; Sarah Stark Casagrande; Shihchen Kuo; William H Herman
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

8.  Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.

Authors:  Xilin Zhou; Sundar S Shrestha; Hui Shao; Ping Zhang
Journal:  Diabetes Care       Date:  2020-07-31       Impact factor: 19.112

Review 9.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Authors:  David Beran; Margaret Ewen; Kasia Lipska; Irl B Hirsch; John S Yudkin
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

10.  Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences.

Authors:  Susan L Karam; Jared Dendy; Shruti Polu; Lawrence Blonde
Journal:  Diabetes Spectr       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.